

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

INSIDE INFORMATION – UPDATE ON PERFORMANCE OF INVESTMENT IN SECURITIES

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (“**Board**”) of directors of the Company (“**Directors**”) wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that based on the information currently available to the Board (including the assessment of the value of the suspended securities as described below), the Company is expected to record a loss on equity instruments at fair value through other comprehensive income on listed securities in Hong Kong of approximately HK\$2.5 million for the six months ended 30 June 2018 (“**2018 Interim Period**”), as compared to an unaudited loss of approximately HK\$65.4 million for the six months ended 30 June 2017. As at 30 June 2018, certain of the Group’s equity instruments at fair value through other comprehensive income comprised listed securities in Hong Kong, the trading of which had been suspended as directed by the Securities and Futures Commission (“**SFC**”). The Company has engaged an independent professional valuer to assess the value of such suspended securities as at 30 June 2018.

As the Company is still in the process of preparing and finalising its unaudited condensed consolidated interim financial information for the 2018 Interim Period (“**2018 Interim Results**”), the information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the information currently available, which has not been audited or reviewed by the auditors of the Company and may be subject to change. The information may also be subject to adjustment after further review and finalisation of the 2018 Interim Results by the Board. Shareholders and potential investors are advised to refer to the details of the Company’s announcement of the 2018 Interim Results, which is expected to be published in August 2018.

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the SFC in accordance with its direction issued under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V of the Laws of Hong Kong). Trading in the shares of the Company will remain suspended until further notice.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

On behalf of the Board
New Ray Medicine International Holding Limited
Liu Yang
Chairman & Executive Director

Hong Kong, 7 August 2018

As of the date of this announcement, the executive Directors are Mr. Liu Yang, Mr. Huo Zhihong and Ms. Wang Qiuqin; and the independent non-executive Directors are Mr. Leung Chi Kin and Ms. Li Sin Ming, Ivy.